Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing Multiple Sclerosis

NCT05834855 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT05834855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05834855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing Multiple Sclerosis
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 3
Overall status
Recruiting
Start date
April 30, 2023
Completion date
May 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases of the nervous system, demyelinating autoimmune diseases, cns, demyelinating diseases, multiple sclerosis, multiple sclerosis, relapsing-remitting, nervous system diseases